(ZTS) Zoetis - Ratings and Ratios

Zoetis Inc. is a leading global animal health company that develops, manufactures, and commercializes a wide range of medicines, vaccines, and diagnostic products for livestock and companion animals. The companys diverse product portfolio includes parasiticides, vaccines, dermatology products, anti-infectives, and pain management solutions, as well as diagnostic tools and precision animal health products. With a strong presence in the United States and internationally, Zoetis markets its products to veterinarians, livestock producers, and pet owners, addressing the growing demand for animal health solutions.

By leveraging its robust research and development capabilities, Zoetis has established collaborations with innovative companies like Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. This strategic partnership underscores the companys commitment to addressing the evolving needs of the animal health industry and capitalizing on emerging opportunities. With a history dating back to 1950, Zoetis is headquartered in Parsippany, New Jersey, and has established itself as a major player in the global animal health market.

From a technical analysis perspective, Zoetis stock price has been trending above its 20-day and 50-day simple moving averages (SMA20 and SMA50), indicating a positive short-term momentum. However, the stock is currently below its 200-day simple moving average (SMA200), suggesting a potential long-term downtrend. The average true range (ATR) of 4.07 represents a 2.41% daily price fluctuation, indicating moderate volatility. Given the current price of 168.63, a potential trading range could be between 164.56 and 172.70, based on the SMA20 and ATR.

Fundamentally, Zoetis market capitalization stands at approximately $74 billion, with a price-to-earnings (P/E) ratio of 29.86 and a forward P/E of 26.88. The companys return on equity (RoE) is a robust 51.32%, indicating strong profitability. By combining these fundamental metrics with technical analysis, a potential forecast for Zoetis could be: if the company continues to demonstrate strong earnings growth and the stock price breaks above its SMA200, it may be poised for a significant upward trend, potentially reaching $185-$190 in the near term. Conversely, if the stock fails to break above its SMA200 and the P/E ratio contracts, a decline to $155-$160 could be expected.